Abbott Laboratories (ABT) to pay $0.27 on May 15, 2017; Fnb PA (FNB) Shorts Down By 25.23%

Abbott Laboratories (NYSE:ABT) is expected to pay $0.27 on May 15, 2017. $1.06 is the ADY. (NYSE:ABT) shareholders before Apr 11, 2017 will receive the $0.27 dividend. Abbott Laboratories’s current price of $43.83 translates into 0.60% yield. Abbott Laboratories’s dividend has Apr 14, 2017 as record date. Feb 21, 2017 is the announcement. The stock increased 0.37% or $0.16 on April 7, reaching $43.83. About shares traded. Abbott Laboratories (NYSE:ABT) has risen 3.62% since September 1, 2016 and is uptrending. It has underperformed by 4.89% the S&P500.

Fnb Corporation PA (NYSE:FNB) had a decrease of 25.23% in short interest. FNB’s SI was 24.63M shares in April as released by FINRA. Its down 25.23% from 32.95 million shares previously. With 5.94 million avg volume, 4 days are for Fnb Corporation PA (NYSE:FNB)’s short sellers to cover FNB’s short positions. The SI to Fnb Corporation PA’s float is 11.96%. The stock decreased 1.44% or $0.21 on April 7, reaching $14.33. About shares traded. F.N.B. Corp (NYSE:FNB) has risen 15.19% since September 1, 2016 and is uptrending. It has outperformed by 6.69% the S&P500.

F.N.B. Corporation is a financial holding company. The company has market cap of $4.56 billion. The Firm operates through four divisions: Community Banking, Wealth Management, Insurance and Consumer Finance. It has a 18.42 P/E ratio. The Company’s Community Banking segment consists of First National Bank of Pennsylvania , which offers services, including commercial and individual demand, savings and time deposit accounts and commercial, mortgage and individual installment loans.

Investors sentiment increased to 1.45 in 2016 Q4. Its up 0.02, from 1.43 in 2016Q3. It is positive, as 21 investors sold F.N.B. Corp shares while 66 reduced holdings. 38 funds opened positions while 88 raised stakes. 171.43 million shares or 9.07% more from 157.17 million shares in 2016Q3 were reported. Logan Cap Mgmt Inc has invested 0.1% in F.N.B. Corp (NYSE:FNB). Nomura Asset Mngmt Communications owns 1,400 shares or 0% of their US portfolio. Fmr Ltd Liability Co accumulated 5.96M shares or 0.01% of the stock. State Street Corp holds 12.14M shares. 54,696 are held by Gsa Cap Prns Limited Liability Partnership. Geode Capital Mgmt Llc accumulated 0.01% or 1.52 million shares. Moreover, Ghp Advsrs has 0.1% invested in F.N.B. Corp (NYSE:FNB) for 32,801 shares. Royal Fincl Bank Of Canada reported 131,299 shares. Virginia Retirement Sys Et Al has 27,500 shares for 0.01% of their portfolio. Wedge Cap Mgmt L L P Nc invested in 0.2% or 1.29 million shares. Prudential Fincl reported 129,910 shares or 0% of all its holdings. Moreover, Balyasny Asset Management Ltd Llc has 0.13% invested in F.N.B. Corp (NYSE:FNB). California State Teachers Retirement Sys invested in 0.01% or 342,066 shares. Barclays Plc holds 54,817 shares or 0% of its portfolio. Blackrock Limited has invested 0% of its portfolio in F.N.B. Corp (NYSE:FNB).

Since November 2, 2016, it had 3 insider buys, and 1 insider sale for $207,413 activity. $309,140 worth of F.N.B. Corp (NYSE:FNB) was sold by MCCARTHY ROBERT J JR on Wednesday, January 25. Shares for $44,606 were bought by Mencini Frank C. On Wednesday, November 2 the insider STANIK JOHN S bought $27,447. Ellsworth Laura E also bought $29,674 worth of F.N.B. Corp (NYSE:FNB) on Tuesday, January 31.

Among 4 analysts covering F.N.B. Corporation (NYSE:FNB), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. F.N.B. Corporation has $19 highest and $13 lowest target. $16’s average target is 11.65% above currents $14.33 stock price. F.N.B. Corporation had 8 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Friday, October 21 by FBR Capital. On Tuesday, December 20 the stock rating was upgraded by FBR Capital to “Outperform”. As per Friday, July 22, the company rating was maintained by FBR Capital.

Investors sentiment increased to 1.01 in 2016 Q4. Its up 0.05, from 0.96 in 2016Q3. It increased, as 83 investors sold Abbott Laboratories shares while 496 reduced holdings. 103 funds opened positions while 481 raised stakes. 1.06 billion shares or 1.63% more from 1.04 billion shares in 2016Q3 were reported. 50,002 are held by Lynch & Assocs In. Cape Cod Five Cents Bancorp holds 0.74% or 108,473 shares in its portfolio. Lathrop Invest Corporation invested in 6,776 shares. Usca Ria Limited Liability reported 36,575 shares. Alpha Cubed reported 0.15% in Abbott Laboratories (NYSE:ABT). Janney Cap Management Ltd Liability Corporation owns 0.01% invested in Abbott Laboratories (NYSE:ABT) for 6,203 shares. Eagle Ridge Mgmt invested in 107,074 shares. Polar Capital Ltd Liability Partnership accumulated 1.26 million shares or 0.77% of the stock. First Republic Mgmt accumulated 767,315 shares or 0.26% of the stock. Inv Counselors Of Maryland accumulated 17,760 shares. Norinchukin Financial Bank The stated it has 164,055 shares or 0.15% of all its holdings. Zwj Inv Counsel Inc holds 0.14% of its portfolio in Abbott Laboratories (NYSE:ABT) for 36,634 shares. First Trust Advsrs Limited Partnership accumulated 582,479 shares. Thomas Story Son Lc has invested 1.24% in Abbott Laboratories (NYSE:ABT). Shelton has 139,040 shares for 0.48% of their portfolio.

Since November 1, 2016, it had 6 buys, and 19 insider sales for $1.40 million activity. On Tuesday, February 28 NATH DEEPAK S. sold $72,669 worth of Abbott Laboratories (NYSE:ABT) or 1,601 shares. Shares for $72,069 were sold by BIRD ROGER on Tuesday, February 28. Blount Sally E. also bought $200,124 worth of Abbott Laboratories (NYSE:ABT) on Tuesday, November 1. Another trade for 89,578 shares valued at $3.63 million was bought by WHITE MILES D. $86,068 worth of Abbott Laboratories (NYSE:ABT) was sold by Mason Heather L on Tuesday, February 28. On Tuesday, January 31 the insider Fussell Stephen R bought $497,394. The insider Contreras Jaime sold 767 shares worth $34,240.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has market cap of $76.02 billion. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 61.21 P/E ratio. The Company’s Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.